{
  "main_header": {
    "sid": 290229,
    "name": "Zydus Lifesci.",
    "stock_name": "Zydus Lifesci.",
    "full_name": "Zydus Lifesciences Ltd",
    "name_url": "stocks-analysis/zydus-lifesci",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "933.10",
    "chg": -2.1,
    "chgp": "-0.22%",
    "dir": -1,
    "prev_price": "935.20",
    "mcapval": "94,078.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 532321,
    "symbol": "ZYDUSLIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE010B01027",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "9.03 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zydus-lifesci-290229-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Zydus Lifesciences Evaluation Revised Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zydus-lifesciences-downgraded-to-sell-amid-technical-weakness-and-financial-concerns-3740605",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZydusLifescienc_mojoScore_3740605.png",
        "date": "2025-12-02 08:32:00",
        "description": "Zydus Lifesciences, a prominent player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market assessment following a detailed analysis of its financial performance, valuation metrics, technical indicators, and overall quality parameters. This article explores the factors influencing the recent shift in the company's evaluation, providing investors with a comprehensive understanding of the underlying data driving these changes."
      },
      {
        "title": "Is Zydus Lifesci. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zydus-lifesci-technically-bullish-or-bearish-3740010",
        "imagepath": "",
        "date": "2025-12-02 08:26:29",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Overview</strong></p>\n<p>The latest technical assessment for Zydus Lifesci. shows a transition from a mildly bullish to a mildly bearish trend. This shift is significant as it reflects a change in market sentiment and momentum. The weekly and monthly charts provide a mixed but predominantly bearish picture, with key momentum indicators signalling caution.</p>\n<p>Specifically, the Moving Average Convergence Divergence (MACD) indicator is bearish on the weekly chart and mildly bearish on the monthly chart. This suggests that the stock’s momentum is weakening over both short and medium terms. Meanwhile, the Relative Strength Index (RSI) does not currently provide a clear signal on either timeframe, indicating a lack of strong directional momentum.</p>\n<p><strong>Price Volatility..."
      },
      {
        "title": "Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-technical-momentum-shifts-amid-mixed-market-signals-3739938",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ZydusLifescienc_technicaldot_3739938.png",
        "date": "2025-12-02 08:03:23",
        "description": "Zydus Lifesciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators across multiple timeframes. The pharmaceutical and biotechnology company’s stock price movements and technical parameters suggest a nuanced market assessment as it navigates recent evaluation adjustments."
      },
      {
        "title": "How has been the historical performance of Zydus Lifesci.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-zydus-lifesci-3739253",
        "imagepath": "",
        "date": "2025-12-01 23:13:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Growth</strong></p>\n<p>Over the seven-year period ending March 2025, Zydus Lifesci. has steadily expanded its net sales from ₹13,165.6 crores in 2019 to ₹23,241.5 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 11.5%, reflecting the company’s successful market penetration and product portfolio expansion. The total operating income mirrors this trend, with no other operating income reported, indicating that core business activities drive revenue growth.</p>\n<p>Operating profit (PBDIT) excluding other income rose significantly from ₹2,983.5 crores in 2019 to ₹7,058.5 crores in 2025, with the operating profit margin improving from 23.4% to 31.3%. This margin expansion suggests enhanced operational efficiency and cost management. Profit af..."
      },
      {
        "title": "Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-technical-momentum-shifts-amid-mixed-indicator-signals-3734569",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZydusLifescienc_technicaldot_3734569.png",
        "date": "2025-11-28 08:01:20",
        "description": "Zydus Lifesciences has exhibited a nuanced shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This development comes amid a complex array of technical indicator signals, reflecting a blend of cautious optimism and underlying bearish pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Zydus Lifesci. Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/zydus-lifesci-downgraded-from-buy-to-hold-by-marketsmojo-on-4-nov-2025-3731087",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZydusLifesci_mojoScore_3731087.png",
        "date": "2025-11-26 09:46:01",
        "description": "Zydus Lifesci., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, providing investors with a clearer perspective on its current standing."
      },
      {
        "title": "Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-technical-momentum-shifts-amid-mixed-market-signals-3730146",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZydusLifescienc_technicaldot_3730146.png",
        "date": "2025-11-26 08:01:42",
        "description": "Zydus Lifesciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of market indicators. While some metrics suggest sideways movement, others reveal subtle bullish and bearish signals, underscoring a nuanced market assessment for the pharmaceutical and biotechnology company."
      },
      {
        "title": "Zydus Lifesciences Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zydus-lifesciences-technical-momentum-shifts-amid-mixed-indicator-signals-3727339",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZydusLifescienc_technicaldot_3727339.png",
        "date": "2025-11-25 08:03:14",
        "description": "Zydus Lifesciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This development comes amid a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s near-term trajectory."
      },
      {
        "title": "Why is Zydus Lifesci. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-zydus-lifesci-fallingrising-3722023",
        "imagepath": "",
        "date": "2025-11-22 00:51:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Over the past week, Zydus Lifesciences has underperformed relative to the benchmark Sensex, registering a decline of 2.06% compared to the Sensex’s gain of 0.79%. This negative trend extends over the last month as well, with the stock falling 7.54% while the Sensex rose by 0.95%. Year-to-date, the stock remains down 4.74%, contrasting with the Sensex’s robust 9.08% gain. Even over a one-year horizon, Zydus Lifesciences has delivered a negative return of 1.86%, while the broader market advanced by 10.47%. These figures highlight a persistent underperformance against the benchmark indices despite the company’s strong fundamentals.</p>\n<p>In the short term, the stock has been on a two-day losing streak, shedding 0.63% in that period. T..."
      }
    ],
    "total": 577,
    "sid": "290229",
    "stock_news_url": "https://www.marketsmojo.com/news/zydus-lifesciences-290229"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "04-Dec-2025",
      "details": "Zydus receives EIR for the injectable facility located at Jarod.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "27-Nov-2025",
      "details": "Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets 10 mg/5 mg and 25 mg/5 mg.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "26-Nov-2025",
      "details": "Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has declared <strong>1100%</strong> dividend, ex-date: 25 Jul 25",
          "dt": "2025-07-25",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has announced <strong>1:5</strong> stock split, ex-date: 06 Oct 15",
          "dt": "2015-10-06",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Zydus Lifesciences Ltd has announced <strong>1:2</strong> bonus issue, ex-date: 05 Apr 10",
          "dt": "2010-04-05",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Zydus Lifesciences Evaluation Revised Amid Mixed Financial and Technical Signals

2025-12-02 08:32:00

Zydus Lifesciences, a prominent player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market assessment following a detailed analysis of its financial performance, valuation metrics, technical indicators, and overall quality parameters. This article explores the factors influencing the recent shift in the company's evaluation, providing investors with a comprehensive understanding of the underlying data driving these changes.

Read More

Is Zydus Lifesci. technically bullish or bearish?

2025-12-02 08:26:29

Technical Trend Overview

The latest technical assessment for Zydus Lifesci. shows a transition from a mildly bullish to a mildly bearish trend. This shift is significant as it reflects a change in market sentiment and momentum. The weekly and monthly charts provide a mixed but predominantly bearish picture, with key momentum indicators signalling caution.

Specifically, the Moving Average Convergence Divergence (MACD) indicator is bearish on the weekly chart and mildly bearish on the monthly chart. This suggests that the stock’s momentum is weakening over both short and medium terms. Meanwhile, the Relative Strength Index (RSI) does not currently provide a clear signal on either timeframe, indicating a lack of strong directional momentum.

Price Volatility...

Read More

Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:03:23

Zydus Lifesciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators across multiple timeframes. The pharmaceutical and biotechnology company’s stock price movements and technical parameters suggest a nuanced market assessment as it navigates recent evaluation adjustments.

Read More

How has been the historical performance of Zydus Lifesci.?

2025-12-01 23:13:49

Revenue and Profit Growth

Over the seven-year period ending March 2025, Zydus Lifesci. has steadily expanded its net sales from ₹13,165.6 crores in 2019 to ₹23,241.5 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 11.5%, reflecting the company’s successful market penetration and product portfolio expansion. The total operating income mirrors this trend, with no other operating income reported, indicating that core business activities drive revenue growth.

Operating profit (PBDIT) excluding other income rose significantly from ₹2,983.5 crores in 2019 to ₹7,058.5 crores in 2025, with the operating profit margin improving from 23.4% to 31.3%. This margin expansion suggests enhanced operational efficiency and cost management. Profit af...

Read More

Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals

2025-11-28 08:01:20

Zydus Lifesciences has exhibited a nuanced shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This development comes amid a complex array of technical indicator signals, reflecting a blend of cautious optimism and underlying bearish pressures within the Pharmaceuticals & Biotechnology sector.

Read More

Zydus Lifesci. Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-11-26 09:46:01

Zydus Lifesci., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, providing investors with a clearer perspective on its current standing.

Read More

Zydus Lifesciences Technical Momentum Shifts Amid Mixed Market Signals

2025-11-26 08:01:42

Zydus Lifesciences has experienced a notable shift in its technical momentum, reflecting a complex interplay of market indicators. While some metrics suggest sideways movement, others reveal subtle bullish and bearish signals, underscoring a nuanced market assessment for the pharmaceutical and biotechnology company.

Read More

Zydus Lifesciences Technical Momentum Shifts Amid Mixed Indicator Signals

2025-11-25 08:03:14

Zydus Lifesciences, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This development comes amid a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively paint a nuanced picture of the stock’s near-term trajectory.

Read More

Why is Zydus Lifesci. falling/rising?

2025-11-22 00:51:59

Recent Price Performance and Market Context

Over the past week, Zydus Lifesciences has underperformed relative to the benchmark Sensex, registering a decline of 2.06% compared to the Sensex’s gain of 0.79%. This negative trend extends over the last month as well, with the stock falling 7.54% while the Sensex rose by 0.95%. Year-to-date, the stock remains down 4.74%, contrasting with the Sensex’s robust 9.08% gain. Even over a one-year horizon, Zydus Lifesciences has delivered a negative return of 1.86%, while the broader market advanced by 10.47%. These figures highlight a persistent underperformance against the benchmark indices despite the company’s strong fundamentals.

In the short term, the stock has been on a two-day losing streak, shedding 0.63% in that period. T...

Read More

View All News